Efficacy and safety of sirolimus in the treatment of gastrointestinal angiodysplasias

Table 2 Patients’ principal characteristics, management, and adverse events

No.	Gender	Age	Disease course	Clinical symptoms	Comorbidities	Past treatment	Dosage of sirolimus	Adverse events
1	Female	66	3 years	Melena	None	Endoscopic	2 mg, q.d.	Mouth ulcers, diarrhea
2	Female	62	6 months	Melena	Bronchial asthma		2 mg, q.d.	Elevated triglycerides
3	Male	49	14 years	Hematochezia	None	Surgery	1 mg, q.d.	Pulmonary infection
4	Female	64	5 years	Melena	Hypertension, bronchial asthma, mitral regurgitation	Endoscopic	2 mg, q.d.	Diarrhea
5	Male	48	11 months	Melena	Hypertension, pituitary tumor, multiple hepatic hemangiomas	Endoscopic	1 mg, q.d.	None
6	Female	68	1 year	Hematochezia	Hypertension, type 2 diabetes		2 mg, q.d.	Mouth ulcers
7	Female	70	20 months	Melena	Aortic valve stenosis with regurgitation, mitral stenosis		2 mg, q.d.	None
8	Female	39	9 years	Melena	None	Endoscopic, Surgery	2 mg, q.d.	Mouth ulcers
9	Male	52	2 years	Melena	Old cerebral infarction		2 mg, q.d.	Mouth ulcers, rash
10	Female	73	8 months	Melena	Pulmonary emphysema		1.5 mg, q.d.	None
11	Female	74	2 years	Melena	Pulmonary emphysema; atrial fibrillation		1 mg, q.d.	None

q.d.: Quaque die.